SEC Form 4 · accession 0001193125-26-390556
Korro Bio, Inc. · KRRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Oliver Dolan
Officer — Senior Vice President, Finance
Period of report
Sep 11, 2026
Accepted (ET)
Sep 14, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001703647
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Sep 11, 2026 | S | 5 | $13.716 | D | 16,241 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026.
- F2The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.51 to $13.85, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.
- F3Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.